Analyst coverage
Small Pharma is followed by the analysts listed below. Please note that any opinions, estimates or forecasts regarding Small Pharma’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Small Pharma or its management. Small Pharma does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
A pipeline of short duration psychedelic programs
Our pipeline targets the development of treatments that provide fast-acting and long-lasting relief, and have in-clinic scalability potential to address the growing mental health crisis.
Years of R&D development
Number of granted patents
CAD$ raised in 2021
Leadership team
Latest press releases
Small Pharma announces further positive data from SPL026 Phase IIa trial in Major Depressive Disorder strengthening topline efficacy results
Statistically significant improvement in anxiety symptoms offers potential in indications beyond depression.
First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028
The Phase I study will compare IV and IM routes of SPL028 administration.
Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
Two new patents approved for issue bringing total to 16 granted patents.
Events & conferences
Join us at our upcoming events and conferences online and around the globe. Register today or review our library of past events.